Elizabeth Ruth Plummer

Author

Also Known As

E PLUMMER, E R Plummer, E Ruth Plummer, E. Plummer, E. R. Plummer, E. Ruth Plummer, E.R. Plummer, Elizabeth Plummer, Elizabeth R. Plummer, Elizabeth Ruth Plummer

Publications

1.7K

Citations

H-Index

Concepts

All Affiliations

Newcastle University Beatson West of Scotland Cancer Centre Institute of Cancer Research Royal Marsden NHS Foundation Trust University College London

About

Elizabeth Ruth Plummer is an author at Newcastle University specializing in medicine, cancer therapeutics, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	19	682
2	Cell Biology	5	5	120
3	Health Sciences	3	3	57
4	Gastroenterology	1	1	62
5	Hepatology	1	1	15

Elizabeth Ruth Plummer

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2 Yvette Drew, Evan A. Mulligan, Wan-Tse Vong, JNCI Journal of the National Cancer Institute	2010	257
Clinicopathological Features of Homologous Recombination–Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival Asima Mukhopadhyay, Elizabeth Ruth Plummer, Ahmed Elattar, Cancer Research Tumoral PathologyParpi SensitivityMedicineHrd GroupMetronomic Therapy	2012	161
Temozolomide Pharmacodynamics in Patients with Metastatic Melanoma: DNA Damage and Activity of Repair Enzymes <i>O</i>6-Alkylguanine Alkyltransferase and Poly(ADP-Ribose) Polymerase-1 Elizabeth Ruth Plummer, Mark R. Middleton, Christopher J. Jones, Clinical Cancer Research	2005	103
Inhibition of Poly(ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma Rachel Daniel, Agata Rozanska, Huw D. Thomas, Clinical Cancer Research	2009	82
Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines Tomasz Zaremba, Patrick Ketzer, Michael Cole, British Journal of Cancer	2009	71
Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers Tomasz Zaremba, Huw D. Thomas, Michael Cole, Biochemical Journal Higher Parp ActivityImmunologyParp ActivityPathologyCancer Patients	2011	71
Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced gastric or gastroesophageal junction cancer from JAVELIN solid tumor phase Ib trial: Analysis of safety and clinical activity. Hyun Cheol Chung, Hendrik‐Tobias Arkenau, Lucjan Wyrwicz, Journal of Clinical Oncology Esophageal CancerImmunologyGastroenterologyPathologyAdvanced Gastric	2016	62
Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699 Rachel Daniel, Agata Rozanska, Evan A. Mulligan, British Journal of Cancer	2010	55
A first-in-human first-in-class (FIC) trial of the monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with advanced solid tumours. Sarah Halford, Paul S. Jones, Sandra Hirschberg, Journal of Clinical Oncology Tumour Glucose UptakeChemoprevention StrategyMonocarboxylate Transporter 1PathologyPharmacotherapy	2017	54
Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules J. C. Murray, Huw D. Thomas, P. Berry, British Journal of Cancer	2014	46

Page 1